Zobrazeno 1 - 10
of 40
pro vyhledávání: '"S. Günzelmann"'
Autor:
Nadezda Basara, E. Roemer, Axel A. Fauser, W Willenbacher, S Günzelmann, A Hartert, Michael G. Kiehl
Publikováno v:
Bone Marrow Transplantation. 27:337-340
Hematopoietic stem cell transplantation (HSCT) is a treatment option for autoimmune diseases but can also cause clinical features similar to those of autoimmune diseases. In some of these cases the autoimmune-like condition is associated with autoimm
Autor:
WI Blau, D. Kirsten, M. G. Kiehl, N Basara, A.A Fauser, M Bischoff, S Günzelmann, B Schmetzer
Publikováno v:
Clinical Transplantation. 14:121-126
Mycophenolate mofetil (MMF), a new immunosuppressive drug successfully used in renal and heart transplant recipients, was used in combination with cyclosporin A (CsA), methotrexate (MTX) and prednisolone for the prophylaxis of acute graft-versus-host
Publikováno v:
Bone Marrow Transplantation. 25:371-376
Mobilization of peripheral blood cell progenitor cells was investigated in 36 healthy sibling donors using three different split doses of glycosylated rhG-CSF (lenograstim). The donors were randomized into three groups: group 1 was given lenograstim
Publikováno v:
Transplantation Proceedings. 33:2220-2222
Autor:
S Günzelmann, M. G. Kiehl, A.A Fauser, M Bischoff, B Schmetzer, Werner Hopfenmüller, N Basara, E Thiel, Martin Schmidt-Hieber, D. Kirsten, E. Roemer, I. W. Blau
Publikováno v:
Clinical transplantation. 21(1)
Allogeneic stem cell transplantation (SCT) is best performed with an HLA-identical sibling donor (matched related donor, MRD) to reduce the risk of early complications such as acute graft-vs.-host disease (aGvHD). However, as only about 30% of recipi
Autor:
E Römer, WI Blau, B Schmetzer, A.A Fauser, D Kirsten, S Günzelmann, N Basara, M Bischoff, M.G Kiehl
Publikováno v:
Transplantation proceedings. 33(3)
TREATMENT FOR GVHD after allogeneic-related and -unrelated BMT is one of the most critical elements in the reduction of transplant-related morbidity and mortality. The high incidence of aGVHD indicates that more effective therapy and prevention of th
Autor:
N, Basara, W I, Blau, M G, Kiehl, B, Schmetzer, M, Bischoff, D, Kirsten, S, Günzelmann, A A, Fauser
Publikováno v:
Clinical transplantation. 14(2)
Mycophenolate mofetil (MMF), a new immunosuppressive drug successfully used in renal and heart transplant recipients, was used in combination with cyclosporin A (CsA), methotrexate (MTX) and prednisolone for the prophylaxis of acute graft-versus-host
Autor:
N, Basara, W, Jelkmann, B, Schmetzer, S, Günzelmann, M, Bischoff, W I, Blau, M G, Kiehl, A A, Fauser
Publikováno v:
Thrombosis and haemostasis. 82(6)
Autor:
S. Günzelmann, H Sanchez, M. Bischoff, I. W. Blau, M. G. Kiehl, N. Basara, D. Kirsten, E. Roemer, A. A. Fauser, E. L. Wocker
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 32(1)
Toxoplasmosis is a rare but often fatal complication that occurs after patients undergo allogeneic hematopoietic stem cell transplant. At our institution, toxoplasmosis was diagnosed in 8 of 301 patients who received stem cell transplants. Disseminat
Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients
Autor:
Nadezda Basara, M Rudolphi, E Römer, Axel A. Fauser, WI Blau, S Günzelmann, H Sanchez, D Kirsten, M Bischoff
Publikováno v:
Bone marrow transplantation. 22(1)
The efficacy and safety of mycophenolate mofetil (MMF) in combination with CsA and prednisolone for the treatment of acute and chronic GVHD (aGVHD and cGVHD, respectively) after BMT and PBSCT from HLA-mismatched and -matched donors was evaluated in a